Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
01:29pm, Thursday, 10'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer
Merc
The Vanguard Health Care Fund's Top 5 Trades
12:52pm, Thursday, 10'th Feb 2022
The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
12:19pm, Thursday, 10'th Feb 2022
Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.
Sanofi-Regeneron Dupixent gets FDA priority review as add-on therapy for kids with eczema
11:12am, Thursday, 10'th Feb 2022 Seeking Alpha
The U.S. Food and Drug Administration granted priority review to Regeneron Pharmaceutical (REGN) and Sanofi (SNY)''s application seeking approval of Dupixent (dupilumab) as an
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
09:51am, Thursday, 10'th Feb 2022
The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Get the In
FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
05:59am, Thursday, 10'th Feb 2022 Regeneron Pharmaceuticals
TARRYTOWN, N.Y. and PARIS , Feb. 10, 2022 /PRNewswire/ -- If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children Regeneron Pharmaceuticals, Inc.
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
05:25pm, Wednesday, 09'th Feb 2022 Zacks Investment Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
04:22pm, Tuesday, 08'th Feb 2022 Zacks Investment Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
4 Pharmaceutical Stocks To Watch In February 2022
02:00pm, Tuesday, 08'th Feb 2022
Should investors be putting these pharmaceutical stocks on their watchlists?
Company News for Feb 7, 2022
02:40pm, Monday, 07'th Feb 2022 Zacks Investment Research
Companies in The News Are: REGN,AON,RCL,VRTS
Four drug makers raked in $14 billion in sales of COVID-19 treatments in 2021. How will they do this year?
11:51am, Monday, 07'th Feb 2022 MarketWatch
The lucrative, new market could be tempered in 2022.
How Did Hedge Funds Regeneron Pharmaceuticals Inc (REGN) Bets Fare?
08:27pm, Sunday, 06'th Feb 2022 Insider Monkey
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors
Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Len Schleifer on Q4 2021 Results - Earnings Call Transcript
05:40pm, Friday, 04'th Feb 2022 Seeking AlphaRegeneron beats fourth-quarter estimates
01:03pm, Friday, 04'th Feb 2022
Regeneron (NASDAQ: REGN) recorded $23.72 EPS in the fourth quarter, which topped the $18.37 analyst estimates by $5.35. In addition, the company reported $4.95 billion in revenue in the same quarter,
Regeneron more than doubles Q4 revenue powered by sales for COVID-19 antibody
01:03pm, Friday, 04'th Feb 2022 Seeking Alpha
Regeneron Pharmaceuticals (REGN) is trading higher in the pre-market on Friday after the companys Q4 2021 financials exceeded expectations
